We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Neurosurgical Navigation Robot Combines AI and Machine Vision to Streamline Procedures

By HospiMedica International staff writers
Posted on 09 Aug 2022

Amidst the increasing demand for minimally invasive surgery, neuro-navigation has become standard in neurosurgery worldwide. More...

Currently, most navigation systems use a “vision-based optical tracking system” during the registration step. Image-guided surgery is used for intra-operative navigation assistance for neurosurgical problems. However, such solutions require some specific space to be maintained between the device cameras, the probe, and the microscope in order to eliminate obstruction. Now, a new autopilot neurosurgical navigation robot that combines robotic technology, artificial intelligence (AI) and machine vision could assist in surgical procedures such as biopsy, deep brain stimulation (DBS), stereoelectroencephalography (SEEG), endoscopic surgery, and external ventricular drainage (EVD).

NaoTrac, a CE-certified neurosurgical navigation robot from Brain Navi Biotechnology (Hsinchu, Taiwan), uses the company’s proprietary Surface Mapping Auto-Registration Technology (SMART) technology that merges machine vision, robotics, and AI to streamline surgical procedures with real-time imaging and minimally invasive outcomes. NaoTrac can be used for surgeries like endoscopic brain surgery, cell implantation, and other operations. NaoTrac’s unique autonomous procedure enables surgical navigation with non-contact registration, pre-operative planning preparation, and choosing the surgery pathway with 3D vision for precise anatomical location.

NaoTrac has achieved approval from Taiwan's Food and Drug Administration (TFDA) and the company is now planning a submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022. Human trials of NaoTrac performed with EVD placement have shown that the results were good to perfect with high precision.

"The results of this report show that the average time spent on the patient registration was 1423.8 seconds. The mean target deviation was 1.68mm, and the mean angular deviation was 1.99 degrees, all within the accepted tolerance for minimal tissue damage," said Dr. Tsung-Lang, Chiu. "NaoTrac has several advantages besides the high precision, like a non-invasive, non-contact patient registration process with a fast and accurate procedure, the system provides precise navigation to the surgical target. It's also user-friendly, and has many other benefits."

Related Links:
Brain Navi Biotechnology 


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
X-Ray Generator
Advantage Plus Generators
New
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.